MedTrace Logo

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

NCT03771040 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 347

Last updated 2020-12-08

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.

Conditions

Interventions

DRUG

Masitinib

DRUG

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Lavinia Davidescu, MD, PhD · University of Medicine and Pharmacy Oradea, Oradea, Romania.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • Argentina
  • Malaysia
  • Peru
  • Philippines
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03771040 on ClinicalTrials.gov